Lilly acquires the OX2 agonist series from Nexera Pharma\u2019s partner Centessa. Nexera Pharma retains milestone and royalty rights and expects mid- to long-term business profit growth.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4565","jir_company_name":"Nexera Pharma Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-04-01","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/04\/4565-20260401-01.pdf","jir_short_summary":"Lilly acquires the OX2 agonist series from Nexera Pharma\u2019s partner Centessa. Nexera Pharma retains milestone and royalty rights and expects mid- to long-term business profit growth.","jir_summary":"### Overview of the M&A\nCentessa Pharmaceuticals Limited, a partner of Nexera Pharma Inc., was acquired by Eli Lilly and Company on March 31, 2026. Centessa\u2019s OX2 agonist series (cleminorexton\/ORX750, ORX142, ORX489) were co-created using Nexera Pharma\u2019s proprietary NxStaR\u2122 technology. Nexera Pharma continues to retain rights to receive milestones and royalties and holds a partial stake in Centessa\u2019s shares.\n\n### Future Outlook and Impact on Corporate Value\nWhile this acquisition has no impact on the full-year consolidated results for the fiscal year ending December 2026, it is expected to contribute to business profit and corporate value enhancement over the mid- to long-term. Nexera Pharma will leverage its NxWave\u2122 GPCR structure-based drug discovery platform to focus on developing new pipelines for metabolic and rare endocrine diseases, thereby continuing to provide innovative pharmaceuticals that meet global unmet medical needs.","jir_financial_highlights":"Maximum Milestone Amount: 694 million USD (approx. 110.9 billion JPY) (Unknown)\nImpact on Full-Year Consolidated Results for Fiscal Year Ending December 2026: None (Unknown)\nExchange Rate (JPY\/USD): 0.006269592476489028 (Unknown)","jir_category":"","jir_hashtags":"#NexeraPharmaInc, #M&A, #JapaneseStocks","jir_key_figures":"Maximum Milestone Amount: 694 million USD (approx. 110.9 billion JPY)\nAcquisition Announcement Date: 2026-03-31\nImpact on Full-Year Consolidated Results for Fiscal Year Ending December 2026: None","jir_meta_title":"Lilly Acquires Nexera Pharma Partner Centessa, Retains 694 Million USD Milestone","jir_meta_description":"Lilly acquires the OX2 agonist series from Nexera Pharma\u2019s partner Centessa. Nexera Pharma retains milestones worth 694 million USD and royalty rights, expecting mid- to long-term business profit growth.","jir_og_title":"Announcement of Completion of Centessa Acquisition by Nexera Pharma Partner","jir_og_description":"Lilly acquires Centessa\u2019s OX2 agonist series. Nexera Pharma continues to hold milestone and royalty rights, anticipating enhancement of corporate value.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":16880,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"m_and_a_alliance","footnotes":""},"sector":[],"importance":[],"class_list":["post-38323","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n